Biotech News

4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics, Inc. (FDMT)4D Molecular Therapeutics, Inc.Earnings

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q3 2026 financial results, provided operational highlights and outlined expected upcoming milestones.

Related news

4D Molecular Therapeutics, Inc.

Genetic Medicines Company 4D Molecular Therapeutics develops genetic medicines using an engineered AAV vector platform known as Therapeutic Vector Evolution. The technology is designed to select vectors for specific tissues and routes of administration rather than relying only on naturally occurring viral capsids. 4D-150 Retinal...

Recent company news

Stock data

Close
10.72 USD
Market cap
484.6M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States